PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

First Posted Date: 2021-10-25

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT05090566

Locations: 🇺🇸
Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸
Banner Gateway Medical Pavilion, Gilbert, Arizona, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 24 locations

This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2021-10-19

Last Posted Date: 2023-03-31

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05082428

Locations: 🇫🇮
Pfizer, Helsinki, Finland

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Primary Immune Thrombocytopenia

Interventions: Biological: PF-06835375

First Posted Date: 2021-10-07

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT05070845

Locations: 🇵🇱
Pratia Onkologia Katowice, Katowice, Poland
🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇦🇺
Clinical Research Unit Haematology, Division of Cancer Services, St. George Hospital, Kogarah, New South Wales, Australia

and more 23 locations

Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.

Terminated

Conditions: Ulcerative Colitis

Interventions: Other: Stool sample collection

First Posted Date: 2021-10-06

Last Posted Date: 2025-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05069259

Locations: 🇨🇭
Kantonsspital St, Gallen, St. Gallen, Sankt Gallen, Switzerland
🇨🇭
Clarunis, Universitätsspital, Basel, Switzerland
🇨🇭
Verein IBD Study Group, Bern, Switzerland

and more 2 locations

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Breast Neoplasms
Endometrial Neoplasms
Ovarian Neoplasms

Interventions: Drug: PF-07260437
Diagnostic Test: B7-H4 IHC

First Posted Date: 2021-10-05

Last Posted Date: 2025-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05067972

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
University of Washington Medical Center - Mountlake, Seattle, Washington, United States
🇵🇷
Pan American Center for Oncology Trials- Hospital Oncologico, Rio Piedras, Puerto Rico

and more 12 locations

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Abrocitinib
Drug: Omeprazole
Drug: Caffeine
Drug: Efavirenz

First Posted Date: 2021-10-05

Last Posted Date: 2024-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT05067439

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06650833
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)

First Posted Date: 2021-10-01

Last Posted Date: 2023-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05064332

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332/ritonavir + Dabigatran
Drug: Ritonavir + Dabigatran
Drug: Dabigatran

First Posted Date: 2021-10-01

Last Posted Date: 2024-03-29

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT05064800

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2021-09-29

Last Posted Date: 2024-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT05061446

Locations: 🇯🇵
NHO Hirosaki General Medical Center, Hirosaki-shi, Aomori-ken, Japan
🇯🇵
Our Lady of the Snow St. Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵
Kudo Internist Heart Clinic, Morioka-shi, Iwate-ken, Japan

and more 76 locations

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Phase 1

Terminated

Conditions: Renal Cell Cancer
Squamous Cell Carcinoma
Sarcoma
Colorectal Cancer
Bladder Cancer
Head and Neck Cancer
Melanoma
Non-Small-Cell Lung Cancer
Hepatocellular Cancer
Ovarian Cancer

Interventions: Biological: PF-07263689
Biological: Sasanlimab

First Posted Date: 2021-09-29

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05061537

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
CUMC Research Pharmacy, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy